What is Cellanome?
Cellanome operates at the intersection of biotechnology and advanced data analytics, offering a sophisticated live-cell, multimodal platform. By integrating molecular, functional, and temporal data from individual cells, the company enables researchers to observe dynamic biological processes with unprecedented clarity. Their flagship R3200 Platform, which encompasses specialized instrumentation, consumables, and software, is engineered to support complex assays in critical fields such as neurobiology, immunology, and oncology. By facilitating the generation of AI-ready datasets, Cellanome is effectively positioning itself as an essential infrastructure provider for modern drug discovery and disease modeling, bridging the gap between raw biological observation and actionable therapeutic insights.
How much funding has Cellanome raised?
Cellanome has raised a total of $75.9M across 1 funding round:
Private Equity
$75.9M
Private Equity (2026): $75.9M, investors not publicly disclosed
Key Investors in Cellanome
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Cellanome?
With this major strategic investment, Cellanome is poised to accelerate the commercial deployment of its R3200 Platform across global research institutions and pharmaceutical enterprises. The company's roadmap likely involves scaling manufacturing capabilities to meet the rising demand for high-resolution cellular analysis while simultaneously enhancing its software suite to better support machine learning-driven modeling. As the firm matures, the focus will shift toward establishing deeper partnerships within the biopharmaceutical industry, aiming to standardize its technology as a foundational tool for precision medicine. By leveraging its unique CellCage technology, Cellanome is well-positioned to capture significant market share in the rapidly evolving landscape of single-cell analysis and predictive biology.
See full Cellanome company page
